Sera from patients with diabetes do not alter the effect of mammalian target of rapamycin inhibition on smooth muscle cell proliferation

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 1, 2009, Pages 86-89

  Moss, Stephanie C ^a   Lightell Jr , Daniel ^a   Deichmann Jr , Richard E ^a   Woods, T Cooper ^a,b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary restenosis; Diabetes mellitus; Metabolic syndrome X; Rapamycin; Vascular smooth muscle

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ADULT; AGED; ARTICLE; BIOCHEMICAL COMPOSITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SERUM; SMOOTH MUSCLE FIBER; ANIMAL; DIABETES MELLITUS; DRUG EFFECTS; DRUG ELUTING STENT; MAMMAL; METABOLISM; MIDDLE AGED; SMOOTH MUSCLE;

AGED; ANIMALS; CELL PROLIFERATION; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MAMMALS; MIDDLE AGED; MUSCLE, SMOOTH; MYOCYTES, SMOOTH MUSCLE; SIROLIMUS;

EID: 67651098785     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318195b588     Document Type: Article

References (15)

1. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634-640.
2. Weisz G, Leon MB, Holmes DR Jr, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006;47:1350-1355.
3. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296-1302.
4. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177-189. (Pubitemid 34876546)
5. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163-175.
6. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164-2170. (Pubitemid 29196802)
7. Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
8. Stettler C, Allemann S, Egger M, et al. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart. 2006;92:650-657.
9. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273-2278. (Pubitemid 38678518)
10. Jonas M, Edelman ER, Groothuis A, et al. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulinresistant and diabetic animals. Circ Res. 2005;97:725-733. (Pubitemid 41416342)
11. Stellbrink E, Schroder J, Grawe A, et al. Impact of metabolic syndrome on clinical and angiographic outcome after sirolimus-eluting stent implantation. Coron Artery Dis. 2007;18:601-606. (Pubitemid 351339512)
12. Hoffmann R, Stellbrink E, Schroder J, et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. Am J Cardiol. 2007;100: 1347-1352. (Pubitemid 47576009)
13. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
14. Martinez-Gonzalez J, Vinals M, Vidal F, et al. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis. 1997;135:213-223. (Pubitemid 28015188)
15. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996; 98:1897-1905. (Pubitemid 26359208)